Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A hybrid deep learning and attention fusion framework for intelligent zero-day threat detection in cloud web application firewalls.

Scientific reports·2026
Same author

Cyanoacetylation of amines <i>via</i> a traceless cyanoacetyl radical: synthetic access to teriflunomide.

Chemical communications (Cambridge, England)·2026
Same author

Retraction notice to "A review on extraction of polysaccharides from crustacean wastes and their environmental applications" [Environ. Res. 221 (2023) 115306].

Environmental research·2026
Same author

Organocatalytic Multicomponent Reactions Using 1,1-Diaminobenzalazine: Synthesis of Pyrano[2,3-<i>c</i>]pyrazoles and Pyranochromenes.

The Journal of organic chemistry·2026
Same author

GIS-based landslide susceptibility zonation using weighted overlay analysis with AHP: a case study of Malappuram district, Kerala, India.

Scientific reports·2026
Same author

Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-<i>a</i>]quinoxalines as dual EGFR and tubulin targeting anticancer agents.

Journal of enzyme inhibition and medicinal chemistry·2026

Related Experiment Video

Updated: Jun 5, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Comparative 3D QSAR study on β(1)-, β(2)-, and β(3)-adrenoceptor agonists.

P Senthil Kumar1, Prasad V Bharatam

  • 1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, (NIPER), Sector 67, S. A. S. Nagar, Mohali, 160 062 India.

Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents
|December 21, 2010
PubMed
Summary

This study used comparative molecular field analysis (CoMFA) to explore tryptamine derivatives as beta-adrenoceptor agonists. The findings reveal distinct structural requirements for binding to beta(1), beta(2), and beta(3) subtypes, aiding in selective drug design.

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
10:16

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets

Published on: March 12, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
10:16

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets

Published on: March 12, 2019

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Pharmacology

Background:

  • Beta-adrenoceptors play crucial roles in cardiovascular and metabolic functions.
  • Developing subtype-selective agonists is essential for targeted therapeutic interventions.
  • Tryptamine derivatives are a promising scaffold for adrenoceptor agonist development.

Purpose of the Study:

  • To elucidate the structure-activity relationships of tryptamine-based beta-adrenoceptor agonists.
  • To identify key chemical features governing subtype selectivity for beta(1), beta(2), and beta(3) receptors.
  • To develop predictive models for designing novel, selective beta-adrenoceptor agonists.

Main Methods:

  • Quantitative structure-activity relationship (QSAR) analysis was performed.
  • Comparative molecular field analysis (CoMFA) was employed for three beta-adrenoceptor subtypes.
  • Correlation coefficients (cross-validated r(2)) were calculated for each CoMFA model.

Main Results:

  • CoMFA models yielded significant predictive power with cross-validated r(2) values of 0.578 (β(1)), 0.595 (β(2)), and 0.558 (β(3)).
  • Distinct steric and electrostatic contributions were identified for each receptor subtype, indicating unique binding pocket requirements.
  • CoMFA contour plots provided insights into critical chemical features influencing biological activity and selectivity.

Conclusions:

  • The study successfully delineated the structural determinants for beta-adrenoceptor subtype selectivity among tryptamine derivatives.
  • The identified structure-activity relationships can guide the rational design of novel agonists with improved selectivity profiles.
  • This research offers a foundation for developing targeted therapies modulating specific beta-adrenoceptor subtypes.